Follicum (“Follicum” or “the Company”) today announces that the company’s grant application to Vinnova to study binding of FOL peptides to receptors on pancreatic cells has been approved. Follicum is the coordinator of the project, which also includes Lund University and SARomics Biostructures. Parts of the project involve advanced analysis work to be performed at […]
Follicum AB (“Follicum” or “the Company”) today announces that it has received approval from the German Medicines Agency (BfArM) and the German Ethics Committee to start a Phase IIa clinical study with a topical formulation of FOL-005 on patients with alopecia (hair loss). The trial will comprise about 200 patients who will be treated with […]
Follicum AB (“Follicum” or “the Company”) today announces that data from studies on human Langerhans islets have shown positive effects on insulin release in line with the previously reported results on beta cells isolated from animals. The studies were performed through two different collaborations, one with Lund University and one with InSphero, Switzerland and showed […]
Follicum announced on September 17, 2019 that the Company had received a so-called Notice of Allowance from the US Patent and Trademark Office (“USPTO”) regarding the patent application “Novel Compositions and Uses Thereof”. Follicum today announces that the patent has now formally been granted by the USPTO. The patent number is US 10,517,932 and the […]
Follicum today announces that the company has signed a collaboration agreement with proDERM for conducting the new clinical trial with a cream-like formulation of FOL-005 to be tested on alopecia patients (patients with hair loss). The company expects to be ready for starting the clinical trial shortly after the turn of the year. Preparations for […]
Follicum today announces that the company’s application for a Eurostars grant comprising the development of a first-in-class treatment for diabetes has been approved. Follicum is the coordinator of the project. Other partners include Lund University, Bioassay Labor für biologische Analytik GmbH and Deutsche Diabetes-Forschungsgesellschaft (DDZ). The grant comprising just under EUR 0.7 M commences December […]
Follicum today announces that the company has successfully completed the supplementary toxicology studies that will form the basis of the forthcoming clinical study with the topical formulation of FOL-005. The company expects to be ready for the start of the clinical study in patients with hairloss (alopecia) in early 2020. Preparations for the clinical trial […]
Follicum today announces that the company has successfully completed the supplementary toxicology studies that will form the basis of the forthcoming clinical study with the topical formulation of FOL-005. The company expects to be ready for the start of the clinical study in patients with hairloss (alopecia) in early 2020. Preparations for the clinical trial […]
Lund, Sweden, September 26. Follicum today announces the signing of a cooperation agreement with Bioglan AB for the production of clinical trial material of Follicum’s new, cream-like formulation of FOL-005 for topical treatment. The formulation will be used in the Phase II clinical trial on hair loss, which is expected to start in the beginning […]
Follicum AB (“Follicum”) announces that the U.S. Patent Office (USPTO) has issued a Notice of Allowance for their patent application 16/176,201 which when granted confers expanded protection for Follicum’s product candidate FOL-005. Follicum has already two granted US patents in this patent family (US 9,381,149 and US 10,137,169), conferring protection for different forms of FOL-005. […]